Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
HKG: 0867
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...
China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea
China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...
CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...